A few days ago, Hainan Laobai Health Technology Co., Ltd. and Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as "Qilu Pharmaceutical") reached a strategic cooperation, and the two sides reached a high consensus on jointly strengthening the construction of the omni-channel pharmaceutical chain and meeting the needs of users throughout the life cycle. This is another important breakthrough in building a closed-loop ecological chain of "medicine + medicine + insurance", and it also marks a big step forward for Laobai Health's digital drug guarantee capability to the industry-leading level.
Laobai Health is one of the pioneers of digital medical welfare management business in China, and its mission is to enhance the accessibility and balance of multi-level medical and drug protection in China, and help users enjoy a healthy and happy life. Relying on its own strong first-class chain capabilities and high-quality and rich service resources, Laobai Health focuses on meeting the drug needs of users for common diseases and chronic diseases, and provides users with end-to-end drug guarantee services from "manufacturer to patient" through in-depth cooperation with upstream pharmaceutical companies, and ensures that the whole process is efficient, safe and controllable.
Qilu Pharmaceutical is a large-scale comprehensive modern pharmaceutical enterprise that is "famous in China and famous abroad", adheres to the "wisdom of the pharmacist", faces the world's frontier of science and technology, faces the people's life and health, vigorously implements the innovation-driven strategy, and has been ranked among the top 10 of the top 100 pharmaceutical industry in China for many years. Relying on the five major R&D centers in China and the United States, we continue to integrate global high-quality resources for innovative drug research and development, and have laid out a rich and competitive or differentiated product pipeline in the fields of unmet major diseases such as tumors, infections, liver diseases, autoimmunity, and metabolic diseases.
Relying on Qilu Pharmaceutical's professional and technical capabilities in the prevention and treatment of tumors and serious diseases, common diseases, and frequent diseases, and Laobai Health's outstanding digital medical welfare management capabilities, the two sides will jointly promote the integration of "Internet + pharmaceutical services", accelerate the improvement of the accessibility of medical services, and help more people enjoy a healthy and beautiful life.
Focusing on user needs, Laobai Health continues to promote the ecological layout of "medical + medicine + insurance" closed-loop services. Up to now, in terms of improving the omni-channel pharmaceutical chain, Laobai Health has reached a consensus on full-line product cooperation with hundreds of well-known pharmaceutical companies, including Qilu Pharmaceutical, and is becoming the preferred partner of more and more pharmaceutical companies to develop channels and strengthen brands. Up to now, the general list of Laobai health drugs covers 85 of the top 100 chemical drugs in public hospitals (excluding injections).7%, covering 90% of the top 100 proprietary Chinese medicines in public hospitals (excluding injections).9%, which has provided medication guarantee for more than 2 million users and helped save more than 100 million yuan in medical expenses.
Building a harmonious, efficient and sustainable industrial ecology is an important symbol of continuous innovation and progress in an industry. At present, Laobai Health is actively exploring the innovation of medical and health service models, and making every effort to promote the professional, refined and intelligent development of medical and health services. In the future, relying on the advantages of the first chain and strong digital intelligence capabilities, the cooperation between Laobai Health and pharmaceutical companies will no longer be limited to drug sales, but will focus on the innovation of diseases and health ecological services, and work together to promote digital medical welfare management into a new era.